Agreement with Daiichi Sankyo

RNS Number : 2295V
AstraZeneca PLC
29 October 2010
 



AstraZeneca AnnounceS Co-Promotion Agreement with Daiichi Sankyo

for NEXIUM in Japan

 

 

 

AstraZeneca today announced an agreement with Daiichi Sankyo for the co-promotion and supply of NEXIUM (esomeprazole magnesium), a proton pump inhibitor, in Japan.

 

Under the terms of this agreement, AstraZeneca and Daiichi Sankyo will co-promote the product after it is approved for use in Japan. AstraZeneca will manufacture and develop the product and Daiichi Sankyo will be responsible for its distribution.

 

Daiichi Sankyo will make an initial payment of $100 million to AstraZeneca, paying further undisclosed sums when the product is approved and sales target milestones are achieved.

 

NEXIUM is approved in more than 120 countries for the treatment of gastroesophageal reflux disease.

 

AstraZeneca first submitted a regulatory application for NEXIUM in Japan in February 2010.

 

- ENDS -

 

NOTES TO EDITORS:

 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009.  For more information please visit: www.astrazeneca.com

 

 

CONTACTS:

 

Media Enquiries:

Neil McCrae                                +44 20 7604 8236 (24 hours)
Sarah Lindgreen                         +
44 20 7604 8033 (24 hours)
Abigail Baron                               +
44 20 7604 8034 (24 hours)

Laura Woodin                             +44 20 7604 8031 (24 hours)

 

Investor Enquiries UK:

Jonathan Hunt                             +44 20 7604 8122mob: +44 7775 704032
Karl Hård                                     +
44 20 7604 8123mob: +44 7789 654364
Clive Morris                                 +
44 20 7604 8124mob: +44 7710 031012

 

Investor Enquiries US:

Ed Seage                                    +1 302 886 4065   mob: +1 302 373 1361
Jorgen Winroth                           +1 212 579 0506   mob: +1 917 612 4043

 

 

29 October 2010

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRLIFLEIILAFII

Companies

AstraZeneca (AZN)
Investor Meets Company
UK 100